콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

D-033

Supelco

Dihydromorphine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C17H21NO3
CAS Number:
509-60-4
Molecular Weight:
287.35
EC Number:
200-659-6
MDL number:
MFCD00190622
UNSPSC 코드:
41116107
PubChem Substance ID:
329798599
NACRES:
NA.24

Grade

certified reference material

형태

liquid

특징

Snap-N-Spike®/Snap-N-Shoot®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

농도

1.0 mg/mL in methanol

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

forensics and toxicology

형식

single component solution

배송 상태

wet ice

저장 온도

−20°C

SMILES string

O[C@@H](CC1)[C@@]2([H])[C@@]3([C@]1([H])[C@H](N(C)CC3)C4)C5=C4C=CC(O)=C5O2

InChI

1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1

InChI key

IJVCSMSMFSCRME-KBQPJGBKSA-N

일반 설명

Dihydromorphine is a semisynthetic opioid analgesic sold under the trade names Paramorfan or Paramorphan for treatment of pain. Dihydromorphine is also a primary active metabolite of the analgesic opioid drug dihydrocodeine. This Snap-N-Spike® Reference Solution is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from urine drug testing and pain prescription monitoring to pharmaceutical research.

법적 정보

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

관련 제품

제품 번호
설명
가격

M-031

Morphine-3-β-D-glucuronide solution, 1 mg/mL in methanol with 0.05% NaOH, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

E-052

Ethylmorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPM-005-01

Morphine N-oxide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPM-005-05

10-Hydroxymorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPM-005-06

10-Oxomorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-003

Morphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-005

Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-006

Morphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-017

Morphine-D3-3-β-D-glucuronide solution, 100 μg/mL in methanol with 0.05% NaOH, ampule of 1 mL, certified reference material, Cerilliant®

M-018

Morphine-3-β-D-glucuronide solution, 100 μg/mL in methanol: water ( 50:50(v/v)), ampule of 1 mL, certified reference material, Cerilliant®

M-030

Morphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-046

Morphine-6-β-D-glucuronide solution, 1.0 mg/mL in methanol: water (2:8), ampule of 1 mL, certified reference material, Cerilliant®

M-085

Morphine-D6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-086

Morphine-D6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-096

Morphine-6-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

M-120

Morphine-6-β-D-glucuronide-D3 solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

N-006

Normorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

픽토그램

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

신호어

Danger

유해 및 위험 성명서

H225,H301 + H311 + H331,H370

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

표적 기관

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point (°F)

49.5 °F - closed cup

Flash Point (°C)

9.7 °C - closed cup

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

R Maggi et al.
European journal of pharmacology, 301(1-3), 169-177 (1996-04-22)
The present study showed that the glucocorticoid/progesterone antagonists, 17 beta-hydroxy-1 1 beta-(4-dimethylamino-phenyl-1)-17-(prop-1-ynyl)estra-4,9-dien+ ++-3-one (RU486) and 17 beta-hydroxy-11 beta-(4-dimethylamino-phenyl-1)-17-(propan-3-ol)estra-4,9-dien-3-o ne (ZK 98299), inhibit the binding of labeled dihydromorphine to mu-opioid receptors present on membrane preparations derived from rat and mouse brain
M Wieczorek et al.
Biochemical pharmacology, 54(2), 283-291 (1997-07-15)
The determination of the relationship between ligand affinity and bioactivity is important for the understanding of receptor function in biological systems and for drug development. Several physiological and pathophysiological functions of bradykinin (BK) are mediated via the B2 receptor. In
Anna K Przybyl et al.
The Journal of organic chemistry, 68(5), 2010-2013 (2003-03-01)
A practical method for the conversion of tetrahydrothebaine to dihydromorphine in 92% yield is described. The procedure should allow more efficient production of opium products and may be easily modified for large-scale synthesis. The conversion of codeine to (8S)-8-bromomorphide, a
M Grauert et al.
Journal of medicinal chemistry, 40(18), 2922-2930 (1997-08-29)
We have synthesized a series of stereoisomeric 6,7-benzomorphan derivatives with modified N-substituents and determined their ability to antagonize the N-methyl-D-aspartate (NMDA) receptor-channel complex in vitro and in vivo. The ability of the compounds to displace [3H]-MK-801 from the channel site
G B Stefano et al.
Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology, 113(3), 369-373 (1996-03-01)
A previous report demonstrated the presence of the newly discovered opiate alkaloid selective and opioid peptide insensitive mu3 receptor in ganglia of several invertebrate- and one vertebrate species as well as in microglial cells that had egressed from these ganglia
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.